Business Pipeline How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup BioPharma DiveCohen says he looked at around two dozen companies since Acorda wound down.PipelineNeuroscienceRead full story pharminent March 24, 2026 (Last updated: March 24, 2026) BioPharma Dive Cohen says he looked at around two dozen companies since Acorda wound down. PipelineNeuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study resultsNext: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers Related Stories Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026 Pipeline Roche scraps two Ionis-partnered Huntington’s drugs pharminent July 9, 2026 Pipeline Keenova eyes Xiaflex as first drug for plantar fibromatosis pharminent July 9, 2026
